In recent years, significant inroads have led to the unprecedented finding that indoleamine 2,3-dioxygenase (IDO) inhibitors can reprogram the host inflammatory milieu to turn a “cold” tumor (non–T-cell inflammatory tumor) into a “hot” tumor (T-cell inflammatory tumor), becoming a research hotspot in the cancer immunotherapy field (13). Here, IDO1 is linked to cancer.